In this online CME self-learning activity:
The term human papillomavirus encompasses a family of DNA viruses that are sexually transmittable and may cause either benign or malignant lesions. They are the leading cause of cervical cancer (CC), with approximately 90% of CC cases attributable to HPV, as well as a major contributor to anogenital and head and neck cancers although many patients infected with HPV will never develop any related symptoms or disease. The prevalence of any form of genital HPV in non-elderly adults in the U.S. is 42.5%, with the slightly higher prevalence in men. While there are over 40 different HPV types that may infect the genital tract, two (types 16 and 18) are associated with 66% of CC cases and two (6 and 11) cause 90% of anogenital warts.
This learning activity has been designed to bring HCPs’ knowledge of HPV vaccination and associated disease prevention up to date and to improve their competence and performance in identifying those who would benefit from vaccination.
The following HCPs: Primary care physicians and pediatricians; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients who would benefit from HPV vaccination.
Commercial Support Disclosure: This activity is supported by educational grants from MERCK.
Learners may participate in this activity free of charge.
Release Date: February 16, 2021 -- Expiration Date: February 16, 2023
Faculty: Elizabeth Lorde-Rollins, M.D., M.Sc.
Faculty introduction, disclosures
Epidemiology, pathophysiology, and risks associated with HPV
Summary and Conclusion
By the end of the session the participant will be able to:
ACCME Activity #201718491ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Elizabeth Lorde-Rollins, MD, MSc, Attending Obstetrician-Gynecologist, Good Samaritan Hospital, has no relevant financial disclosures.
Disclosure of Educational Planner: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Disclosure of Peer Reviewers:
Daron Brown, MD, has received financial compensation from consulting work and/or research grants from Merck and PDS, Inc.
W. Martin Kast, MD, has received financial compensation from consulting work from Brooklyn Therapeutics, AOV, Onconetics, Karma, Kiromics, Nutcracker, IMV, and Repetoire
Commercial Support Disclosure: This activity is supported by an educational grant from MERCK.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.